Blueshift Asset Management’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

Blueshift Asset Management’s Portfolio CERE Stock Details CERE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-10,791	Closed	-$441K	–	496
2024 Q2	$441K	Buy	10,791 +4,054	+60%	+$169K	0.15%	190
2024 Q1	$285K	Buy	+6,737	New	+$283K	0.15%	207
2022 Q2	–	Sell	-10,268	Closed	-$359K	–	1060
2022 Q1	$359K	Buy	+10,268	New	+$300K	0.03%	558

Other funds holding CERE

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

BTI

Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return

Blueshift Asset Management's CERE Position: Q3 2024 in Review

Blueshift Asset Management sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q3 2024, closing a stake of 10,791 shares — an estimated $441K sold.

Blueshift Asset Management first reported a position in CERE in Q1 2022 and held it in 3 quarters. The position peaked at $441K in Q2 2024. 2 funds tracked by Wall St. Rank hold CERE as of Q3 2024.

Blueshift Asset Management reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
Blueshift Asset Management sold 10,791 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q3 2024, an estimated $441K.
Blueshift Asset Management first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q1 2022 and held it in 3 quarters.
Blueshift Asset Management's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $441K in Q2 2024.
2 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q3 2024.

Based on Blueshift Asset Management's 13F filing for Q3 2024, filed 13 Nov 2024.